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Abstract
Background: Sodium butyrate (NaB) is a histone deacetylase (HDAC) inhibitor exhibiting anti-inflammatory and
neuroprotective effects in a rat ischemic model of stroke as well as a myocardial ischemia model. Although clinical
evidence shows that older women are at higher risk for stroke occurrence and greater stroke severity, no studies
have evaluated the effectiveness of NaB either in females or in older animals.
Methods: To determine the effects of NaB on stroke in older females, acyclic middle-aged Sprague-Dawley female
rats (9–11 months old, constant diestrus) were subject to middle cerebral artery occlusion (MCAo) by intracerebral
injection of recombinant endothelin-1. Rats were treated with NaB (300 mg/kg, i.p.) at 6 and 30 h following ET-1
injection. Animals were sacrificed at the early (2 days) or late (5 days) acute phase after MCAo. Serum and tissue
lysates were collected for biochemical analyses.
Results: NaB treatment reduced infarct volume and ameliorated sensory motor impairment in middle-aged female
rats, when measured at 2 and 5 days post MCAo. At the early acute phase (2 days post stroke), NaB treatment
decreased brain lipid peroxides, and reduced serum levels of GFAP, a surrogate marker of blood-brain barrier (BBB)
permeability. NaB also reduced expression of the inflammatory cytokine IL-1beta in circulation and IL-18 in the
ischemic hemisphere. At the late acute phase (5 days post stroke), NaB treatment further suppressed MCAo-induced
increase of IL-1beta, IL-17A, and IL-18 in brain lysates (cortex and striatum) from the ischemic hemisphere, and
decreased ischemia-induced upregulation of IL-1beta and IL-18 in circulation, indicating a potent anti-inflammatory
effect of the HDAC inhibitor. Moreover, NaB treatment also increased expression of IGF-1, a known neuroprotectant,
in peripheral tissue including serum, liver, and spleen at the late acute phase.
Conclusions: These data provide the first evidence that delayed (>6 h) NaB treatment post-stroke is neuroprotective
in older female rats. Additionally, these data also show that in addition to its well-known anti-inflammatory actions, NaB
may exert a biphasic effect after stroke, operating initially to reduce BBB permeability and oxidative stress in the brain,
and later, elevating IGF-1 expression in peripheral tissues.
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Background
Stroke is the fifth-leading cause of death in the USA
and the most common cause of disability [1]. Ischemic
stroke is more prevalent in the elderly, and among this
population, postmenopausal women have a higher risk
for stroke occurrence, greater stroke severity, and slower
recovery [2, 3]. Recent preclinical studies have accurately
replicated the demographic differences in which aging
female mice present increased stroke damage as compared
to aging male mice [4]; and acyclic middle-aged female
rats show greater infarct volume and behavioral deficit as
compared to young female rats [5].
Histone acetylation and deacetylation are the two major
players in epigenetic mechanisms to regulate transcription
and other functions in cells including neurons, microglia,
and astrocytes. Protein acetylation, catalyzed by histone
acetyltransferases (HATs), at histone proteins results in an
open chromatin conformation, thus stimulating transcrip-
tion and activating gene expression. The other modifier,
histone deacetylases (HDACs), catalyzes deacetylation of
histone proteins at lysine (Lys, K) residues, hence inhibit-
ing transcription and gene expression. The levels of his-
tone acetylation (thereby remodeling chromatin structure)
is determined by the balance between HATs and HDACs.
In general, HDACs function as a transcriptional repressor
to silence gene expression and induce chromatin compac-
tion. Therefore, HDAC inhibition alters the balance to-
wards enhancing histone acetylation, chromatin relaxation
and gene expression [6, 7]. Histone hypoacetylation and
chromatin compaction have been reported in rodent
studies of middle cerebral artery occlusion (MCAo). A
fatty acid derived HDAC inhibitor, sodium butyrate (NaB)
blocks class I and IIa HDACs and is known to readily
cross the BBB [8]. NaB exhibits anti-inflammatory and
neuroprotective effects in a rat ischemia model of
stroke as well as myocardial infarction through multiple
mechanisms including reducing infarct volume, enhancing
neurogenesis, and reducing pro-inflammatory cytokines in
the ischemic brain [9–14]. Administration of NaB imme-
diately after MCAo (and at various time points) presents
neurogenic effects mediated by the BDNF-TrkB signaling
pathways and anti-inflammatory effects by blocking indu-
cible nitric oxide and COX-2 induction in a male rodent
model of ischemia [11, 13].
Unfortunately, no studies have evaluated the effect-
iveness of the HDAC inhibitors in animal models that
approximate stroke prone groups such as elderly females.
Older women are more likely to suffer a stroke and have
worse stroke impairment, thus the present study tested
the effectiveness of delayed NaB administration in middle-
aged female rats during the early and late acute phase after
cerebral ischemia. The early acute phase of stroke spans
minutes to hours (24–48 h) after ischemia, and is marked
by excitotoxicity including increased reactive oxygen
species, glutamate release, with activation of local in-
flammatory cells and rapid necrotic cell death of neurons
[15, 16]. During the late acute phase, inflammation per-
sists and apoptotic cell death is observed as well as repair
and regeneration such as neurogenesis, angiogenesis and
sprouting [17, 18]. Our data shows that NaB treatment to
middle age female rats after stroke modifies key features
of the acute phase of ischemic stroke.
Methods
Ethics statement
All experimental protocols were approved by the Texas
A&M University Institutional Animal Care and Use
Committee. All animal care and use was conducted in
accordance with the Guide for the Care and Use of
Laboratory Animals (National Research Council).
Animals and estrous cycle determination
Female Sprague-Dawley rats (n = 75) were purchased
from Envigo (Houston, TX) as middle-aged animals
(9–11 months, 280–360 g). All animals were main-
tained in temperature (22 °C) and humidity (45–55%)
controlled environment with a 12/12 h dark-light cycle
(0700 to 1900 h). Rats were fed pelleted food (Harlan,
Teklad Rodent Diet) and water ad libitum. One week
after arrival, animals were subject to daily vaginal
smears to determine estrous status as reported previ-
ously [19]. Briefly, collected vaginal cells were placed
on slides and cell cytology was examined. Middle-aged
female rats were selected if cell cytology indicated they
were in constant diestrus for at least seven consecutive
days. To confirm estrus status, serum samples were
collected and measured for estradiol (Cayman Chemical,
MI). Serum estradiol levels in this group were below the
detection limit (< 6.6 pg/ml) of the assay.
Middle cerebral artery occlusion (MCAo) and sodium
butyrate treatment
MCAo was induced by intracerebral injection of
endothelin-1 (ET-1) to the MCA as previously described
[20]. Animals were anesthetized (100 mg/ml/kg ketamine
and 20 mg/ml/kg xylazine) and placed in a stereotaxic
apparatus. ET-1 (3 microliters of 0.5 μg/μl, 600 pmol) was
injected at a rate of 1 microliter per minute to the left
middle cerebral artery (AP: +0.9, ML: −3.4, relative to
bregma, DV: −8.5, relative to dura). After the surgery,
rats were treated with NaB (Sigma-Aldrich, MO, 300 mg/
kg, i.p.) at 6 and 30 h following ET-1 injection.
Infarct volume
Animals were euthanized at the early (2 days) or late
(5 days) acute phase after MCAo. Brains were quickly
removed and sliced coronally at 2-mm thickness. The
sections were immersed in 2% 2,3,5-triphenyltetrazolium
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chloride (TTC) in DPBS for 30 min at 37 °C and proc-
essed for imaging. The digitized images were used to
quantify infarct volume using the Quantity One soft-
ware package (Bio-Rad, CA). Infarct volume estimation
was performed as reported previously [5]. Briefly, the
posterior (caudal) face of each section from three con-
secutive sections was analyzed in each animal. The in-
farct area of two adjacent slices was averaged and then
multiplied by the thickness of the slice, and values
across all slices were added to obtain the volume of the
infarct. The volume of the ischemic zone and the total
volume of non-ischemic hemisphere was measured sep-
arately, and infarct volume is reported as the ratio of
the ischemic volume to the non-ischemic hemisphere.
Behavioral assays
Motor impairment following MCAo was assessed using
the vibrissae-evoked forelimb placement task [5] and the
adhesive-tape test [21] as described previously. The
vibrissae-elicited forelimb placement test was used 3 and
2 days before and 2 and 5 days after the MCAo surgery.
Animals were subject to same-side placing trials and
cross-midline placing trials elicited by brushing the ipsi-
and contra-lesional vibrissae against the edge of a table.
During the same-side forelimb placing trials, the animal’s
ipsilesional vibrissae were stimulated against the edge of
a table and forelimb placing response on that side was
scored by an investigator, who was blinded to experi-
mental conditions. In the cross-midline placing trials,
the animal was held gently by the upper body such that
the ipsilesional vibrissae lie perpendicular to the table
top and the forelimb on that side is gently restrained as
the vibrissae was brushed on the top of the table to
evoke a response from the contralesional limb and vice
versa. Between each trial the animal was allowed to rest
all four limbs briefly on the table top to help relax its
muscles. Ten trials were performed during each test.
The adhesive tape test was performed 2 days before
and 2 or 5 days after surgery. Two pieces of adhesive-
backed foam tape (Scotch Permanent Mounting Squares,
12.7 × 12.7 mm) were used as bilateral tactile stimuli at-
tached to the palmar surface of the paw of each forelimb.
For each forelimb, the time it took to remove each stimu-
lus (tape) from the forelimbs was recorded during three
trials per day for each forepaw. Animals were allowed to
rest for 1 min between sessions, and each test session had
a maximum time limit of 120 s.
Protein extraction and quantification
Cortex (parietal and temporal) and striatum from the
ischemic and non-ischemic hemisphere, liver, and spleen
samples were collected and homogenized in lysis buffer
(50 mM Tris, pH 7.4, 150 mm NaCl, 10% glycerol,
1 mM EGTA, 1 mM Na-orthovanadate, pH 10, 5 μM
ZnCl2, 100 mM NaF, 10 μg/ml aprotinin, 1 μg/ml leu-
peptin, 1 mM phenylmethylsulfonyl fluoride in dimethyl-
sulfoxide, 1% Triton X-100), and lysates were collected
after centrifugation at 20,000g for 30 min. Protein
concentrations were determined using the BCA protein
assay kit (Pierce, IL) and the plates were read at 562 nm
in a microplate reader (Tecan Infinite® 200 PRO).
Cytokine/chemokine measurements
Expression levels of a panel of inflammatory cytokine/
chemokine were quantified using a rat cytokine/chemokine
panel (Millipore, MA). The procedure was performed
according to the manufacturer's directions. Samples,
standards, and controls were added to appropriate wells
in a 96-well plate as stated in the kit protocol and incu-
bated with premixed beads at room temperature for 2 h
on a horizontal orbital microplate shaker. After washes
(2X), 25 μL of detection antibodies was added to each
well, incubated at room temperature for 1 h on the shaker,
and 25 μL of streptavidin-phycoerythrin was added to
each well containing the 25 μL of detection antibodies.
After 30 min of incubation at room temperature, the wells
were washed (2X) and filled with sheath fluid. The plate
was read on a Bio-Plex System (Bio-Rad, CA). Brain
cytokines and chemokine levels were normalized to total
protein concentrations.
Measurement of serum and tissue IGF-1 levels
IGF-1 levels were measured using a commercial solid
phase sandwich rat ELISA kit (R&D systems, MN) as per
manufacturer's instruction. Samples, standards, and con-
trols were added to appropriate wells in a 96 well plate as
stated in the kit protocol and incubated at room
temperature for 2 h on a horizontal orbital microplate
shaker. After wash, 100 μL of conjugate was added to each
well and incubated at room temperature for 2 h on the
shaker. After wash and incubation in substrate solution
for 30 min, the plates were read at 450 nm in a plate
reader with wavelength correction to 540 nm (Tecan US
Inc., Durham, NC). Sample measurements were interpo-
lated from the standard curve, and values from tissue
lysates were normalized to total protein concentrations.
Measurement of serum and tissue IGFBP-3 levels
IGFBP-3 levels were measured using a commercial ELISA
kit (Crystal Chem, IL) as per manufacturer's instruction.
Samples, standards, and controls were added to appropri-
ate wells in a 96 well plate as stated in the kit protocol and
incubated at room temperature for 1 h on a horizontal
orbital microplate shaker. After washes (5X), 100 μL of
antibody conjugate was added to each well and incubated
at room temperature for 1 h on the shaker. After washes
(5X), 100 μL of enzyme conjugate was added to each well
and incubated at room temperature for 15 min on the
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shaker. After wash and incubation in 100 μL of sub-
strate solution for 15 min in a dark room, 100 μL of
stop solution was added and the plates were read at
450 nm in a plate reader with wavelength correction to
630 nm (Tecan US Inc., Durham, NC). Sample mea-
surements were interpolated from the standard curve,
and values from tissue lysates were normalized to total
protein concentrations.
Measurement of serum GFAP levels
Glial fibrillary acidic protein (GFAP) levels were mea-
sured using a commercial ELISA kit (Millipore, MA) as
per manufacturer’s instruction. Samples, standards, and
controls were added to appropriate wells in a 96 well
plate as stated in the kit protocol and incubated at room
temperature for 2 h on a horizontal orbital microplate
shaker. After washes (4X), 100 μL of biotinylated anti-
GFAP detection antibody was added to each well and
incubated at room temperature for 1 h on the shaker.
After wash, 100 μL of enzyme solution was added to
each well and incubated at room temperature for 30 min
on the shaker. After washes (6X) and incubation in
100 μL of substrate solution for 15 min in dark room,
100 μL of stop solution was added and the plates were
read at 450 nm in a plate reader (Tecan US Inc., Durham,
NC). Sample measurements were interpolated from the
standard curve.
Thiobarbituric acid reactive substances (TBARS) assay
Lipid peroxidation in the ischemic and non-ischemic
hemispheres was determined using the TBARS assay kit
(Cayman Chemical, MI) according to manufacturer’s
instructions and as described previously [22]. Briefly, a
mixture of 25 μl of sample, standard and 25 μl of SDS
was prepared. To this mixture, 1 ml of color reagent was
added and boiled for an hour in boiling water bath. The
reaction was stopped on ice by 10 min incubation and
centrifuged for 10 min at 1600g at 4 °C. The supernatant
(150 μl) was loaded on a 96-well plate and absorbance
was read at 540 nm in Tecan plate reader. TBARS
concentration was calculated from a malondialdehyde
standard curve using Magellan software and normalized
to the amount of total protein.
Statistical analysis
Power analysis, using data from pilot studies and other
experiments using middle aged females, estimated sam-
ple size at five. Most groups had a larger sample size,
with five as the minimum. For infarct volume, a two-way
ANOVA coded for treatment and day was used. For be-
havioral tests, a paired Student’s t test was used for each
group, comparing the values obtained pre- and post-
stroke. For all other comparisons an unpaired Student’s
t-test or a two-way ANOVA was used. Group differences
were considered significant at p < 0.05 in each case. All
data presented in bar graphs are the mean ± S.E.M. from
multiple determinations. Specific animal numbers used
for an assay is described in each figure legend.
Results
Sodium butyrate reduces post-stroke brain infarct volume
Sodium butyrate (NaB), a short chain fatty acid that
blocks class I and IIa HDACs [7], was examined for its
neuroprotective effects following stroke in middle-aged
female rats. Twelve-month-old female rats were sub-
jected to MCAo by ET-1 and injected with vehicle or
NaB (300 mg/kg, i.p.) at 6 h after ET-1 injection,
followed by another injection at 30 h after stroke onset.
Figure 1a shows representative TTC-stained coronal
sections of two animals from each group and Fig. 1b
presents the quantification of the infarct volume nor-
malized to the non-ischemic hemisphere. As shown in
Fig. 1a, all of the groups showed cortical and striatal
infarction, however, the extent of cell death was signifi-
cantly affected by treatment [F (1, 21), 19.93, p = 0.0002]
and day [F (1, 21), 6.96, p = 0.0154] (Fig. 1b). Post-stroke
NaB treatment significantly decreased brain infarction at
2d (T-test, p = 0.0476, n = 6/group), and 5d (t test, p =
0.0018, n = 6–7/group) (Fig. 1b). The neuroprotective
effect of post-stroke NaB at resulted in a 30% decrease in
infarct volume at day 2 and a 63% decrease at day 5 as
compared to post-stroke saline group (Fig. 1b).
Percent body weight change, as an indicator of sick-
ness and safety of NaB treatment, was also measured
during 24 h and 5 days post stroke (Fig. 1c). The extent
of body weight change was significantly affected by
treatment [F (4, 46), 4.46, p = 0.0409] (Fig. 1c). Relative
body weight change showed that the percent weight
loss post MCAo was significantly reduced in NaB-
treated animals (−2.013 ± 0.52%, n = 13) compared to
control (−5.112 ± 0.63%, n = 14) during 24 h after MCAo
(Fig. 1c).
Sodium butyrate treatment ameliorates stroke-induced
loss of sensory motor function
MCAo results in motor and sensory deficit in patients and
animal models [23, 24]. To measure the extent of motor
impairment following MCAo, two tests were utilized.
Vibrissae-evoked forelimb placement task: In the ‘same
side’ test at 2 days post stroke, both post-stroke saline-
and NaB-treated rats displayed significantly lower per-
cent correct responses in the contralesional paw place-
ment (p < 0.0001, n = 6), but not on the ipsilesional side
(p > 0.9999, n = 6) (Fig. 2a). In contrast to 2 days, 5 days
post-stroke saline-treated rats displayed significantly
lower percent correct responses in the contralesional
paw placement (p < 0.0001, n = 7–9), but not on the ipsile-
sional side (p > 0.9999, n = 7–9) (Fig. 2b). Importantly,
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a b
c
Fig. 1 Sodium butyrate reduces brain infarct volume. Middle-aged female rats were subjected to MCAo and injected with two doses of vehicle
or sodium butyrate each at 6 and 30 h after ET-1 injection. a Representative pictures of TTC-stained coronal sections from vehicle (saline)- or NaB
(300 mg/kg, i.p.)-treated female rats at 2 and 5 days post stroke. b Quantitative analysis of infarct volume, expressed as a ratio to the non-ischemic
hemisphere, shows that post-stroke NaB treatment significantly decreased infarct size compared to control at 2 and 5 days post stroke. c Percent body
weight change during 24 h and 5 days post stroke, normalized to pre-stroke weight, indicates percent weight loss post MCAo is significantly reduced
in NaB-treated animals as compared to control group during 24 h after MCAo. Graphs represent mean ± S.E.M, n = 6–7 in each group. Unpaired t test
(b) and two-way ANOVA, Tukey’s multiple comparisons test (c), **p < 0.01, *p < 0.05. b: main effect of treatment, p < 0.05
a b
c d
Fig. 2 Post stroke sodium butyrate treatment improves percent correct responses in the vibrissae-elicited forelimb placement test. a The same
side test of the vibrissae-elicited forelimb placement task at 2 days shows both post-stroke saline- (MCAo + Sal) and NaB-treated (MCAo + NaB)
animals display significantly reduced percent correct responses in the contralesional paw placement as compared to pre-stroke, but not in the
ipsilesional side. b At 5 days post stroke, control treated animals showed significant deficits in paw-placement on the contralesional side compared
to the pre-stroke test. NaB-treated animals showed no significant difference in contralesinal paw-placement pre and post stroke. No pre and post
stroke differences were seen on the ipsilesional side. c, d In the cross-midline test of the vibrissae-elicited forelimb placement task, all groups showed
reduction in correct responses at 2 days (c) and 5 days (d). (All graphs represent mean ± S.E.M. n = 7–9 in each group; ****p < 0.0001; paired t test
between pre and post. a: main effect of time (pre and post), p < 0.05; b: main effect of treatment, p < 0.05; c: main effect of interaction, p < 0.05
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no significant alterations were observed in post-stroke
NaB-treated rats both in the contralesional (p = 0.0880,
n = 7–9) and ipsilesional (p > 0.9999, n = 7–9) paw
placement (Fig. 2b), indicating improved sensory motor
function in post-stroke NaB group as compared to
post-stroke saline treated animals at 5 days. This result
is consistent with the decreased infarct volume in the
post-stroke NaB group at 5 days (Fig. 1b). In the cross-
midline test, both post-stroke saline- and NaB-treated
animals showed significant post-stroke sensory motor
deficit in the contralesional and ipsilesional paw place-
ment at 2 and 5 days (Fig. 2c, d).
Sensory motor performance was also assessed by the
latency to remove an adhesive pad from the forepaw
(adhesive tape test). Post-stroke performance on con-
tralesional paw was significantly impaired in both post-
stroke saline and post-stroke NaB-treated animals at 2d
(Fig. 3a, p < 0.0001 and p = 0.0208, respectively). Notably,
the latency to tape removal from post-stroke NaB
treated group (31.56 ± 6.93 s) was significantly reduced
as compared to post-stroke saline treated group (76.08 ±
16.87 s, p = 0.0499, t test), indicating better sensory
motor function in post-stroke NaB-treated animals at
the early acute phase (2 days post stroke). At 5 days post
stroke, the latency to tape removal on contralesional
paw was significantly reduced in saline-treated group as
compared to pre-stroke latency (p < 0.0001) while no sig-
nificant difference was found in pre- and post-stroke la-
tency of NaB-treated animals (p = 0.8083), indicating
significantly better sensory motor function in post-
stroke NaB-treated animals (Fig. 3b).
Combined, these data indicate that NaB attenuates
MCAo-induced sensory motor deficit in middle-aged
female rats (Figs. 2 and 3).
NaB reduces blood brain barrier permeability in the early
acute phase
HDAC inhibitors are reported to augment blood brain
barrier integrity [10]. We assessed blood-brain barrier
permeability by measuring serum levels of glial fibril-
lary acidic protein (GFAP), which is a well-known bio-
marker of brain injuries including stroke and trauma
[25–27]. Post-stroke saline-treated animals displayed a
threefold higher serum level of GFAP (12.52 ± 3.11 ng/
ml) as compared to post-stroke NaB-treated group
(4.62 ± 0.84 ng/ml, n = 6, p = 0.0175, two-way ANOVA
and Tukey’s multiple comparison) at 2 days, indicating
NaB treatment attenuated BBB disruption (Fig. 4a). At
5 days, serum GFAP levels were low, and the two groups
did not show significant differences.
NaB reduces lipid oxidation in brain in the early acute phase
HDAC inhibitors including NaB have shown to attenuate
oxidative damage in animal models of bipolar disorder,
diabetes, and cancer [28–31]. To assess the effect of NaB
on MCAo induced oxidative stress, we measured the
levels of thiobarbituric reactive species (TBARS), as a
proxy marker of reactive oxygen species [32, 33]. As
shown in Fig. 4b, c, at 2 days post stroke TBARS values
display a main effect of treatment (NaB) in both hemi-
spheres (Fig. 4b, p = 0.0025) whereas at 5 days there was
no differences among the treatment groups (Fig. 4c, p =
0.2210), indicating that NaB promotes an early protective
effect on ischemia-induced oxidative stress in brain.
NaB-mediated neuroprotection after stroke is associated
with the anti-inflammatory effect in circulation and brain
Ischemia induces inflammation, which exacerbates cell
death and prolongs recovery from stroke injury. Circulating
a b
Fig. 3 Sodium butyrate treatment improves the latency of tape removal post ischemia. a The latency (in seconds) to tape removal from the
forepaw was evaluated before (pre) or after (2 days post) MCAo. Post-stroke performance on the ipsilesional paw in both saline- and NaB-treated
animals was not significantly impaired at 2 days. However, post stroke performance on the contralesional paw was significantly worse in both
groups. Latency to adhesive removal was significantly lower in the NaB treated group as compared to saline controls. b At 5 days post MCAo,
post-stroke performance on the ipsilesional paw was not affected in either the saline- or NaB-treated animals. On the contralesional paw, post-stroke
performance was significantly impaired in saline-treated animals, while no significant differences were found in post-stroke NaB-treated group. All
graphs represent mean ± S.E.M. n = 7–9 in each group; *p < 0.05; paired t test between pre and post. a main effect of time (pre and post), p < 0.05;
b main effect of treatment, p < 0.05; c main effect of interaction, p < 0.05
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cytokine levels were examined in serum obtained from the
saphenous vein before (baseline) and after (2 and 5 days)
stroke. The pro-inflammatory cytokine, IL-1beta, was sig-
nificantly affected by treatment [F (1, 30), 11.91, p = 0.0017].
Serum IL-1beta was significantly elevated in post-stroke
saline-treated group at day 2 (68.68 ± 7.19 pg/ml) compared
to the levels of baseline (39.76 ± 2.11 pg/ml; p = 0.0419),
while the NaB-treated group maintained similar levels
at baseline (38.45 ± 4.35 pg/ml), 2d (32.88 ± 4.12 pg/ml,
p = 0.4491 baseline vs. 2 days), and 5 days (25.09 ±
4.72 pg/ml, p = 0.8559 baseline vs. 5 days) post stroke
(Fig. 5a). Another pro-inflammatory cytokine, IL-18,
was also decreased in post-stroke NaB-treated group
(166.2 ± 20.34 pg/ml) as compared to the levels in post-
stroke saline-treated group (249.1 ± 25.49 pg/ml) at
5 days (p = 0.0366) (Fig. 5c). There was no significant
differences in IL-17A levels among the treatment groups
(Fig. 5b).
Analyses of cytokines in the ischemic hemisphere at 2d
post-stroke showed that only one pro-inflammatory cyto-
kine, IL-18, was affected by post-stroke NaB treatment
(Fig. 6c, 611.1 ± 34.12 pg/mg protein vs. 515.1 ± 30.23 pg/
mg protein, p = 0.0467, n = 12/group), while IL-1beta
(Fig. 6a, 69.86 ± 9.58 pg/mg protein vs. 74.73 ± 12.48 pg/
mg protein, p = 0.7598, n = 12/group) and IL-17A (Fig. 6b,
67.62 ± 6.05 pg/mg protein vs. 67.51 ± 6.31 pg/mg protein,
p = 0.9902, n = 11-12/group) were not affected. At 5 days
post stroke, NaB-treatment reduced expression of brain
IL-1beta (Fig. 6d, 123.0 ± 5.69 pg/mg protein vs. 97.05
± 10.19 pg/mg protein, p = 0.0419, n = 11–12/group),
IL-17A (Fig. 6e, 64.55 ± 8.79 pg/mg protein vs. 36.85 ±
8.39 pg/mg protein, p = 0.0344, n = 11–12/group), and
IL-18 (Fig. 6f, 1911 ± 437.3 pg/mg protein vs. 907.8 ±
180.9 pg/mg protein, p = 0.0350, n = 11–13/group) in
the ischemic hemisphere (cortex + striatum).
The protective effect of NaB against ischemia is
associated with elevated levels of insulin-like growth
factor-1 (IGF-1)
NaB has been shown to regulate several members of the
IGF-1 signaling pathway [34, 35]; however, its effect on
IGF-1 per se is not well established. Since IGF-1 is a
known neuroprotectant for stroke in young and aging
animals, we next investigated IGF-1 levels in serum and
corticostriatal samples from ischemic and non-ischemic
hemispheres Consistent with previous reports [19, 20,
22, 36–38], ET-1 induced MCAo elevated IGF-1 level in
ischemic hemisphere in the control (69%) and NaB
treated (61%) (Fig. 7a). Ischemia significantly increased
brain IGF-1 levels at 2d post stroke, however, brain IGF-
1 levels were not affected by NaB treatment [F (1,10),
2.19, p = 0.1697] (Fig. 7a). No significant alteration was
observed in IGF-1 levels from serum, liver, and spleen
between groups at 2 days post stroke (Fig. 7b–d).
Fig. 4 NaB treatment attenuates stroke-induced serum GFAP and brain TBARS at 2 days post stroke. a GFAP levels were measured from serum
samples at 2 and 5 days post stroke. (B-C) TBARS levels were assessed from brain lysates at 2d (b) and 5d post stroke (c). All graphs represent
mean ± S.E.M. n = 3–6 in each group. *p < 0.05 a: main effect of treatment, b: main effect of time, c: interaction effect (treatment X time). Two-way
ANOVA with Tukey’s post hoc test. Repeated measures analysis (ischemic and non-ischemic hemisphere) for TBARS data
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Similar to the pattern seen at 2 days post stroke, brain
IGF-1 levels at 5 days post stroke were only affected by
ischemia (hemisphere) [F (1,10), 10.92, p = 0.0079], but
not by NaB treatment [F (1,10), 0.74, p = 0.4098] (Fig. 8a).
Strikingly, 5d IGF-1 analysis showed that post-stroke
NaB treatment significantly elevated IGF-1 expression
by 28% in serum (1097.89 ± 75.51 vs. 859.66 ± 30.22 ng/
ml), by 46% in liver (3123.82 ± 245.99 pg/mg protein vs.
2140.81 ± 345.89 pg/mg protein), and by 34% in spleen
(996.86 ± 53.78 vs. 746.12 ± 92.41 pg/mg protein) as com-
pared to post-stroke saline treated group (Fig. 8b–d).
Hence, NaB effects on IGF-1 were restricted to peripheral
tissues.
IGF-binding protein-3 (IGFBP-3) is increased in ischemic
hemisphere as compared to non-ischemic hemisphere
post stroke
The IGF signaling pathway includes ligands (IGF-1
and -2), receptor (IGF-1R), and binding proteins (IGFBPs)
[39]. Since IGFBP-3 is a major circulating IGFBP, which
binds >75% of serum IGFs, we next measured IGFBP-3
levels in brain, serum, liver, and spleen at 2d and 5d post
stroke. Figures 9a and 10a show that IGFBP-3 is signifi-
cantly affected by hemisphere, but not by NaB treatment
in brain. Similarly, NaB did not affect IGFBP3 expres-
sion either at 2 or 5 days post stroke in serum (Figs. 9b
and 10b), liver (Figs. 9c and 10c), and spleen (Figs. 9d
and 10d).
Discussion
Our data provide the first evidence that post-stroke
NaB treatment is neuroprotective in middle-aged re-
productive senescent female rats. In this study, we show
that two i.p. injections (6 and 30 h after MCAo) of NaB
significantly reduced cortical and striatal infarct volume
and ameliorated stroke-induced loss of sensory motor
function. Preclinical studies have identified NaB as a po-
tential therapeutic drug for ischemic stroke [11, 40, 41],
although these studies have mainly utilized young male
animals. While older women have a higher risk for stroke
and poorer recovery as compared to aged men, no studies
have evaluated the effectiveness of HDAC inhibitors in
clinically relevant animal models such as aged animals or
females. Furthermore, few studies have treated NaB at a
delayed time point (>6 h) following stroke, which is a
critical question for stroke therapy [42]. The present study
convincingly demonstrates that delayed NaB administra-
tion is effective for middle-aged female rats after cerebral
ischemia.
While NaB is generally shown to improve stroke out-
comes, its mechanism of action appears to be pleio-
tropic. During the acute phase poststroke, NaB reduces




Fig. 5 The effect of NaB on inflammatory cytokines in serum. Cytokine levels from serum were evaluated by ELISA on samples obtained at
baseline, 2 and 5 days post stroke for IL-1beta (a), IL-17A (b), and IL-18 (c). All graphs represent mean ± S.E.M. n = 6–9 in each group. **p < 0.01;
*p < 0.05; two-way ANOVA with Tukey’s post hoc test
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a b
c d
Fig. 7 Central and peripheral levels of IGF-1 at 2 days post stroke. IGF-1 levels were measured from cortex and striatum (a), serum (b), liver (c),
and spleen (d) samples collected at 2 days post MCAo.(a) ***p < 0.001 main effect of hemisphere. Two-way ANOVA. (b–d) Unpaired t test. All
graphs represent mean ± S.E.M. n = 6 in each group. ICS ischemic cortex and striatum, NICS non-ischemic cortex and striatum
a b c
d e f
Fig. 6 The effect of NaB on inflammatory cytokines in the ischemic hemisphere post stroke. Cytokine levels were measured by ELISA in corticostriatal
tissue lysates from the ischemic hemisphere at 2d (a–c, n = 6/group) and 5 days (d–f, n = 10–13/group) post stroke. All graphs represent mean ± S.E.M.
**p < 0.01; *p < 0.05; unpaired t test
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whereas, during the delayed phase poststroke, NaB pro-
motes cell survival and tissue repair and recovery [43, 44].
At the early phase (ranging from minutes to hours), react-
ive oxygen species are released from injured cells, further
stimulating the release of inflammatory cytokines as well
as matrix metalloproteinases, which act in concert to in-
crease blood brain barrier permeability and trafficking of
leukocytes [15, 16]. Delayed actions of NaB may contrib-
ute to stroke recovery and repair in two ways: one, by
elevating IGF-1 in periphery tissues, which may trigger
remodeling responses in both endothelial cells and
astrocytes [22, 45] and additionally, by decreasing pro-
inflammatory cytokines such as IL-17. IL-17 is produced
by gammadeltaT lymphocytes, and infiltration of this T
cell cohort in the brain during the acute phase of stroke
been shown to promote infarction and brain damage [44].
Decreased IL-17 production in NaB group is thus consist-
ent with the reduced infarct volume seen in this group
and reducing this inflammatory cytokine may further pro-
mote repair processes in delayed phase of stroke.
Unlike its action on lipid peroxides and IGF-1, NaB
suppression of inflammatory cytokines spanned the early
and late acute phase of stroke. Our data show that NaB
decreased pro-inflammatory cytokine levels of IL-1beta
in circulation at 2 days post stroke and both IL-18 and
IL-1beta at 5 days post stroke. In the ischemic hemi-
sphere, NaB decreased IL-18 at 2 days post stroke and
IL-1beta, IL-17a, and IL-18 at 5 days post stroke. Our
previous studies show that neither of these proteins are
significantly different in young or middle aged females
[46], and are likely driven by ischemic injury. Proinflam-
matory cytokines released during ischemic stroke have a
detrimental effect on neuronal survival and functional
recovery [47, 48]. Lower levels of IL-18 by NaB at both 2
and 5 days post stroke is particularly interesting in view of
the data that this cytokine is reported to have prognostic
value in patients with acute ischemic stroke [49–51]. IL-
18 is synthesized peripherally by macrophages and human
peripheral blood mononuclear cells [52, 53] and by micro-
glia, astrocytes, and neurons in central nervous system as
the first response of immune defense [54–56]. Zaremba
and colleagues have shown that serum IL-18 level is
significantly elevated in stroke patients as compared to
controls, and IL-18 levels were negatively correlated with
both the Scandinavian Stroke Score and the Barthel Index
[50]. Moreover, circulating IL-18 levels from blood drawn
48 h after ischemic stroke was a major predictor of 90-day
major adverse clinical outcomes in this cohort [49]. These
clinical reports are consistent with our observation in
middle-aged female rats where higher IL-18 levels in the
a b
c d
Fig. 8 NaB treatment increases IGF-1 levels in peripheral tissues but not brain at 5 days post stroke. IGF-1 levels were determined by ELISA from
cortex + striatum (a), serum (b), liver (c), and spleen (d) samples collected at 5d post MCAo. a IGF-1 levels are significantly elevated in the ischemic
hemisphere; however, there is no difference in IGF-1 level between treatment groups in either the ischemic or non-ischemic hemisphere. ***p < 0.001
main effect of hemisphere. b–d Post-stroke NaB treatment increased serum (b), liver (c), and spleen (d) levels of IGF-1 as compared to post-stroke
vehicle-treated group. **p < 0.01; unpaired t test. All graphs represent mean ± S.E.M. n = 6 in each group. ICS ischemic cortex and striatum, NICS non-
ischemic cortex and striatum
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saline-treated group is accompanied by worse sensory
motor function as compared to the post-stroke NaB-
treated group. In addition to the clinical data, preclin-
ical studies using myeloid cells have shown that HDAC
inhibitors including NaB, valproic acid and TSA increase
expression of IL-18 mRNA [57].
We also found lower levels of IL-17A by NaB in the
ischemic hemisphere only at later acute phase of stroke
(5 days, Fig. 6e), but not at early acute phase (Fig. 6b),
while in peripheral tissues lower levels of IL17A were
found both at 2 and 5 days (Fig. 5b). This may imply
migration of Th17 cells to the brain at later acute phase
of stroke, which is initially activated from periphery at
the earlier acute phase. It is plausible because HDAC
inhibitors are reported to regulate T cell polarization,
by which HDAC inhibition suppresses the polarization
toward the pro-inflammatory Th17 cells [58]. Our data
also suggest that NaB protect the brain from neuroinflam-
matory responses, in part, by suppressing peripheral im-
mune responses by reducing trafficking of T-cells.
While the effects of NaB on inflammatory cytokines are
extensively studied, its effects on IGF-1 are not well
known. The IGF-1 signaling pathway is a critical biological
modulator of cellular growth, development, and metabol-
ism [39]. Our laboratory has previously demonstrated
that stroke severity in older females is associated with
decreased IGF-1 availability [20] and IGF-1 treatment,
provided intracerebroventricularly, after stroke protects
the aging brain by reducing blood brain barrier disrup-
tion and neuroinflammation [22]. Interestingly, while
NaB significantly increases IGF-1 in peripheral tissues
in the post stroke animal, there was no elevation of
IGF-1 in the brain with this treatment. In a study
examining the biodistribution of exogenous fatty acids
including n-butyric acid (BA), 4-phenylbutyric acid
(PBA) and valproic acid in primates [59], only a very
small amount (<0.006%) is taken up by the brain,
whereas majority of these fatty acids were taken up by
spleen (BA) and liver (PBA). Considering this biodistri-
bution, it is not surprising that NaB was most effective
in IGF-1 level in liver, spleen, and serum. The relation-
ship between NaB and IGF-1 is poorly understood. NaB
has been shown to cause a dose dependent increase in
IGFBP3 and IGFBP2 protein and mRNA [34], proteins
that are known to store and increase the half-life of
IGF-I. Since the dose of NaB used in this study has
a b
c d
Fig. 9 IGFBP-3 level is increased in ischemic hemisphere at 2 days post stroke. IGFBP-3 levels were measured from cortex and striatum (a), serum
(b), liver (c), and spleen (d) samples collected at 2 days post MCAo. IGFBP3 levels are significantly elevated in the ischemic hemisphere compared
to the non-ischemic hemisphere. NaB did not affect IGFBP3 expression in any of these tissue. All graphs represent mean ± S.E.M. n = 6 in each
group. ***p < 0.001 main effect of hemisphere. Two-way ANOVA (a) and unpaired t test (b–d). ICS ischemic cortex and striatum, NICS non-ischemic
cortex and striatum
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been reported to restore MCAo-induced decrease in
histone acetylation [13], another likely possibility is that
increased IGF-1 expression pathway may result from
increased transcription due to preservation of histone
acetylation.
Stroke-induced inflammation, and the trafficking of
immune cells to the ischemic brain is a critical feature of
stroke pathophysiology. Young, cycling females typically
display small infarct volumes with fewer T cells in the
brain after stroke [60], which is positively correlated with
serum estradiol levels. Loss of this ovarian hormone in
aged females was associated with increased stroke out-
come and splenic contraction. In a comprehensive ana-
lysis of the central and peripheral immune response to
MCAo, Zhang et al. reported that in estrogen-deficient
females, stroke increased splenic Treg cells and reduced
splenocyte proliferation and thymocyte numbers, while
estrogen replacement reduced infarct volume, decreased
splenic Treg cell numbers and increased splenic prolifer-
ation [61]. These data suggest that the loss of estrogen
in middle aged females likely exacerbates the immune
cell invasion to the brain and causes worse outcome post
stroke. It is also consistent with the idea that NaB may
improve infarct volume in this population by modulating
the inflammatory response.
While aged women are likely to have a higher risk for
stroke, worse outcomes and poorer recovery after the
event compared to aged men, preclinical studies rou-
tinely failed to utilize clinically relevant animal models,
such as aged female model. The present study suggests
that readily supplementable and clinically well-tolerated
NaB could be an effective treatment to improve sensory
motor function and outcome after acute ischemic stroke
in middle-aged females, suggesting that HDAC inhibi-
tors might have utility in treating acute stroke in a broad
range of demographics. While several studies show that
sodium butyrate is neuroprotective, the precise mechan-
ism is unclear, and is likely to be multi-pronged, involv-
ing anti-inflammatory, anti-apoptotic and growth factor
mediated pathways [9]. The current study shows that
NaB may target peripheral organs to promote central
nervous system health.
Conclusions
The results of the present study with a HDAC inhibitor,
sodium butyrate (NaB) provide the first evidence that
delayed NaB treatment post-stroke is neuroprotective in
middle-aged reproductive senescent female rats. Our data
indicate that two doses of NaB by i.p. injection (6 and





Fig. 10 IGFBP-3 level is increased in ischemic hemisphere at 5 days post MCAo. IGFBP-3 levels were measured from cortex and striatum (a), serum
(b), liver (c), and spleen (d) samples collected at 5 days post stroke. IGFBP3 levels are significantly elevated in the ischemic hemisphere compared
to the non-ischemic hemisphere. NaB did not affect IGFBP3 expression in any of these tissue. All graphs represent mean ± S.E.M. n = 6 in each
group. ***p < 0.001 main effect of hemisphere. Two-way ANOVA (a) and unpaired t test (b–d). ICS ischemic cortex and striatum, NICS non-ischemic
cortex and striatum
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infarct volume and significantly attenuates loss of sensory
motor function. The neuroprotection of NaB against
MCAo is associated with an anti-inflammatory effect of
this HDAC inhibitor. Additionally, our data show that
NaB also an early anti-oxidant effect and a later trophic
effect, specifically, elevating IGF-1, which we have previ-
ously shown is a robust neuroprotectant for stroke in
aging females.
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